NCT01250470View on ClinicalTrials.gov

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 5, 2012

Primary Completion Date

May 29, 2014

Study Completion Date

May 29, 2014

Conditions
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaGiant Cell GlioblastomaGlioblastomaGliosarcomaMixed GliomaRecurrent Brain Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Montanide ISA-51/Survivin Peptide Vaccine

Given SC

BIOLOGICAL

Sargramostim

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | Biotech Hunter | Biotech Hunter